Clinical Trial Detail

NCT ID NCT02513667
Title Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors University of Texas Southwestern Medical Center
Indications

lung adenocarcinoma

Therapies

Ceritinib

Age Groups: adult

Additional content available in CKB BOOST